Patients with malignant pleural mesothelioma (MPM) lived 6 months longer, on average, when they had surgery in addition to chemotherapy, a large retrospective analysis showed. The addition of surgery ...

The MARS2 trial put the mesothelioma treatment community off its axis, at least in terms of whether these patients should undergo surgery. The phase III study showed that extended pleurectomy ...

Although surgery can prolong the lives of patients with an aggressive type of cancer called malignant pleural mesothelioma, many patients avoid the operation for fear it will degrade their quality of ...

Empyema often co-occurs with pneumonia and refers to the presence of pus in the pleural space. There is a range of therapeutic options available for the management of empyema, the primary aim being to ...

Intrapleural enzyme therapy (IET) improves outcomes in adult inpatients with complicated parapneumonic pleural effusion or empyema.

We conducted a phase II trial to evaluate the effects on local control and survival of combining surgery with intraoperative photodynamic therapy (PDT), a light-based cancer treatment, in patients ...

TCT 417: Ten-Year Clinical Outcomes After Randomization to PCI of a Concurrent Chronic Total Coronary Occlusion or Optimal Medical Therapy Alone in Patients With STEMI: Extended Follow-Up of the ...

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer ...